Aktienanalyse zu HUTCHMED (China) Ltd (HCM)HCMHUTCHMED (China) Ltd

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

HUTCHMED (China) Ltd is a good buy right now due to its current price of $14.36, which is below the analyst price targets of $16 to $18.50, indicating potential upside. The forward P/E ratio of 18.08 suggests that the stock is reasonably valued compared to future earnings expectations, while the recent positive news regarding licensing agreements with GSK is expected to generate significant revenue streams. However, the high P/E ratio of 1269.60 poses a risk, indicating that the stock may be overvalued if future growth does not meet expectations.

4 analysts cover HCM: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 22.00.